Process development with Chinese Hamster Ovary and hybridoma cell lines: Differences, challenges, things to know

Joint Event on 13^th International Conference on Biologics and Biosimilars & Biopharma & Biotherapeutics

October 24-25, 2018 | Boston, USA

Robert Swift

Invenux LLC Windsor, US

Scientific Tracks Abstracts: J Bioanal Biomed

Abstract :

When utilizing different cell lines, expression, productivity and upstream process design, in general, need to be adapted to the metabolism and behavior of these cells. In the upstream process, critical to achieving high biosimilar yields are the choice of the expression system and cell line. For biosimilars, this a rapidly changing landscape as biosimilar manufacturers are no longer bound by technologies used decades ago to produce the original biologic. This Workshop will discuss these choices for Chinese Hamster Ovary (CHO) and Hybridoma cell lines.

Biography :

Robert Swift is trained as a molecular biologist and virologist. He is the managing member of Invenux, LLC, a clincial stage pharmaceutical company.

E-mail: robert@invenux.com